News & Events about Arcellx Inc.
Arcellx, Inc. (NASDAQ:ACLX Get Rating) saw a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 2,710,000 shares, an increase of 13.4% from the December 31st total of 2,390,000 shares. Currently, 10.6% of the shares of the ...
Arcellx, Inc. (NASDAQ:ACLX Get Rating) was the target of a significant drop in short interest in the month of December. As of December 15th, there was short interest totalling 2,460,000 shares, a drop of 13.7% from the November 30th total of 2,850,000 shares. Approximately 11.1% of the ...
Arcellx, Inc. (NASDAQ:ACLX Get Rating) was the target of a significant drop in short interest in the month of December. As of December 15th, there was short interest totalling 2,460,000 shares, a drop of 13.7% from the November 30th total of 2,850,000 shares. Approximately 11.1% of the shares of the...
Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced a global strategic collaboration to co-develop and co-commercialize Arcellxs lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple...
Arcellx Announces Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma and Additional Pipeline Progress Arcellx Announces Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in...